Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Research Abstract |
We identified that Telmisartan, a hypertensive medicine and iseffective in preventing cardiovascular events in high-risk patients, could activate humancoronary artery endothelial cells (HCAECs) by modulating mitochondrial function.Telmisartan improves endothelial dysfunction through the upregutation of AMPK signaling,a key regulator of cellular energy adaptation, in HCAECs. In vivo, Telmisartan alsoimproved endothelial dysfunction in KKAY mouse model.
|